ImmSygma™
Engineering the Future
of Vaccine Adjuvants
A fully synthetic glycomolecule platform designed to enable safer, scalable, and globally accessible vaccines.
Why ImmSygma™?
Six reasons synthetic glycomolecules
are the next step for adjuvants
ImmSygma™ is not a molecule — it is a chemistry engine.
ImmunAdd exists to make potent vaccine adjuvants sustainable. We replace extraction with total chemical synthesis, so adjuvant supply is set by design and manufacturing capacity, not by harvest yield. Read More →
Technology
Redefining Vaccine Adjuvants Through Synthetic Glycomolecule Innovation
We are building the world’s first synthetic glycomolecule adjuvant platform for next-generation vaccines. By replacing natural extraction with total chemical synthesis, ImmSygma™ makes potent adjuvants designable, reproducible and scalable.
About
ImmunAdd at a glance
ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in pharmaceutical and industrial sectors.
